Identification

Name
Asenapine
Accession Number
DB06216
Type
Small Molecule
Groups
Approved
Description

Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.

Structure
Thumb
Synonyms
Not Available
External IDs
ORG-5222
Product Ingredients
IngredientUNIICASInChI Key
Asenapine MaleateCU9463U2E285650-56-2GMDCDXMAFMEDAG-CHHFXETESA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SaphrisTablet5 mgSublingualMerck Ltd.2011-12-19Not applicableCanada
SaphrisTablet5 mg/1SublingualAllergan2013-09-30Not applicableUs
SaphrisTablet5 mg/1SublingualOrganon2009-08-13Not applicableUs
SaphrisTablet10 mg/1SublingualStat Rx USA2009-08-142018-02-08Us
SaphrisTablet5 mg/1SublingualOrganon2010-06-21Not applicableUs
SaphrisTablet2.5 mg/1SublingualAllergan2014-12-30Not applicableUs
SaphrisTablet10 mgSublingualMerck Ltd.2011-12-19Not applicableCanada
SaphrisTablet10 mg/1SublingualAllergan2013-09-30Not applicableUs
SaphrisTablet10 mg/1SublingualOrganon2009-08-13Not applicableUs
SaphrisTablet10 mg/1SublingualOrganon2010-06-21Not applicableUs
International/Other Brands
Saphris / Sycrest (Lundbeck )
Categories
UNII
JKZ19V908O
CAS number
65576-45-6
Weight
Average: 401.84
Monoisotopic: 401.103000462
Chemical Formula
C21H20ClNO5
InChI Key
GMDCDXMAFMEDAG-BTJKTKAUSA-N
InChI
InChI=1S/C17H16ClNO.C4H4O4/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19;5-3(6)1-2-4(7)8/h2-8,14-15H,9-10H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
IUPAC Name
(2Z)-but-2-enedioic acid; 17-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.0²,⁶.0⁷,¹²]octadeca-1(14),7,9,11,15,17-hexaene
SMILES
OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1

Pharmacology

Indication

Used for treatment in psychosis, schizophrenia and schizoaffective disorders, manic disorders, and bipolar disorders as monotherapy or in combination.

Associated Conditions
Pharmacodynamics

Asenapine is a serotonin, dopamine, noradrenaline, and histamine antagonist in which asenapine possess more potent activity with serotonin receptors than dopamine. Sedation in patients is associated with asenapine's antagonist activity at histamine receptors. Its lower incidence of extrapyramidal effects are associated with the upregulation of D1 receptors. This upregulation occurs due to asenapine's dose-dependent effects on glutamate transmission in the brain. It does not have any significant activity with muscarinic, cholinergic receptors therefore symptoms associated with anticholinergic drug activity like dry mouth or constipation are not expected to be observed. Asenapine has a higher affinity for all aforementioned receptors compared to first-generation and second-generation antipsychotics except for 5-HT1A and 5-HT1B receptors.

Mechanism of action

Asenapine is an atypical antipsychotic multireceptor neuroleptic drug which shows strong 5HT2A (serotonin) and D2 (dopamine) receptor antagonism, which has been shown to enhance dopamine (DA) and acetylcholine (Ach) efflux in rat brains. Asenapine may improve cognitive function and negative symptoms in patients with schizophrenia.

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
U5-hydroxytryptamine receptor 1A
antagonist
Human
U5-hydroxytryptamine receptor 1B
antagonist
Human
U5-hydroxytryptamine receptor 2B
antagonist
Human
U5-hydroxytryptamine receptor 2C
antagonist
Human
U5-hydroxytryptamine receptor 5A
antagonist
Human
U5-hydroxytryptamine receptor 6
antagonist
Human
U5-hydroxytryptamine receptor 7
antagonist
Human
UAlpha-2A adrenergic receptor
antagonist
Human
UAlpha-2B adrenergic receptor
antagonist
Human
UAlpha-2C adrenergic receptor
antagonist
Human
UAlpha-1A adrenergic receptor
antagonist
Human
UD(1A) dopamine receptor
antagonist
Human
UD(3) dopamine receptor
antagonist
Human
UD(4) dopamine receptor
antagonist
Human
UHistamine H1 receptor
antagonist
Human
UHistamine H2 receptor
antagonist
Human
UBeta-1 adrenergic receptor
antagonist
Human
UBeta-2 adrenergic receptor
antagonist
Human
Absorption

Cmax, single 5 mg dose = 4 ng/mL (within 1 hour); Bioavailability, sublingual administration = 35%; Bioavailability, oral administration (swallowed) = <2%; Time to steady state, 5 mg = 3 days; Peak plasma concentration occurs within 0.5 to 1.5 hours. Doubling dose of asenapine results in 1.7-fold increase in maximum concentration and exposure. Drinking water within 2-5 minutes post administration of asenapine results in a decrease in exposure.

Volume of distribution

20-25 L/kg

Protein binding

95% protein bound

Metabolism

Asenapine is oxidized via CYP1A2 and undergoes direct glucuronidation via UGT1A4. Oxidation via CYP1A2 is asenapine's primary mode of metabolism.

Route of elimination

Urine (50%) and feces (50%)

Half life

24 hours (range of 13.4 - 39.2 hours)

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Asenapine.Experimental
(4R)-limonene(4R)-limonene may decrease the antihypertensive activities of Asenapine.Investigational
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Asenapine.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Asenapine.Investigational
2,5-Dimethoxy-4-ethylamphetamineAsenapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineAsenapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineAsenapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineAsenapine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Asenapine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Asenapine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Asenapine can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Asenapine.Approved, Investigational
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Asenapine.Approved, Investigational
AceclofenacAceclofenac may decrease the antihypertensive activities of Asenapine.Approved, Investigational
AcemetacinAcemetacin may decrease the antihypertensive activities of Asenapine.Approved, Experimental, Investigational
AcepromazineAsenapine may increase the antihypertensive activities of Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Asenapine is combined with Aceprometazine.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Asenapine.Approved, Investigational, Withdrawn
Acetyl sulfisoxazoleThe metabolism of Asenapine can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetylcholineThe risk or severity of adverse effects can be increased when Asenapine is combined with Acetylcholine.Approved
AcetyldigitoxinAsenapine may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinAsenapine may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Asenapine.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Asenapine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Asenapine is combined with Adipiplon.Investigational
AdrafinilAsenapine may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Asenapine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Asenapine is combined with Agomelatine.Approved, Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Asenapine.Experimental, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Asenapine is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Asenapine.Approved, Withdrawn
AlfaxaloneThe risk or severity of adverse effects can be increased when Asenapine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Asenapine.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Asenapine.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Asenapine.Approved, Vet Approved
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Asenapine.Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Asenapine is combined with Allopregnanolone.Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Asenapine.Experimental
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Asenapine.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Asenapine.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Asenapine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Asenapine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Asenapine.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Asenapine.Approved, Withdrawn
AmantadineThe therapeutic efficacy of Amantadine can be decreased when used in combination with Asenapine.Approved
AmbenoniumAmbenonium may increase the bradycardic activities of Asenapine.Approved
AmibegronAsenapine may decrease the vasoconstricting activities of Amibegron.Investigational
AmiodaroneThe therapeutic efficacy of Asenapine can be increased when used in combination with Amiodarone.Approved, Investigational
AmisulprideAsenapine may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitrazAmitraz may increase the atrioventricular blocking (AV block) activities of Asenapine.Vet Approved
AmitriptylineAsenapine may increase the antihypertensive activities of Amitriptyline.Approved
AmlodipineThe risk or severity of hypotension can be increased when Asenapine is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Asenapine.Approved, Illicit
AmodiaquineThe metabolism of Asenapine can be decreased when combined with Amodiaquine.Approved, Investigational
AmoxapineAsenapine may increase the antihypertensive activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Asenapine is combined with Amperozide.Experimental
AmphetamineAsenapine may decrease the stimulatory activities of Amphetamine.Approved, Illicit, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Asenapine is combined with Amrinone.Approved
AnagrelideThe risk or severity of QTc prolongation can be increased when Anagrelide is combined with Asenapine.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Asenapine.Investigational
AnisodamineAsenapine may decrease the vasoconstricting activities of Anisodamine.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Asenapine.Approved, Investigational
ApalutamideThe serum concentration of Asenapine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApocyninApocynin may decrease the antihypertensive activities of Asenapine.Investigational
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Asenapine.Approved, Investigational
ApraclonidineAsenapine may decrease the vasoconstricting activities of Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Asenapine.Approved, Investigational
AprepitantThe serum concentration of Asenapine can be increased when it is combined with Aprepitant.Approved, Investigational
AranidipineThe risk or severity of hypotension can be increased when Asenapine is combined with Aranidipine.Approved, Investigational
ArbutamineAsenapine may decrease the vasoconstricting activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Asenapine is combined with Arecoline.Experimental
ArformoterolArformoterol may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
AripiprazoleAsenapine may increase the antihypertensive activities of Aripiprazole.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Asenapine.Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Asenapine.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Asenapine is combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Asenapine is combined with Articaine.Approved
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Asenapine.Approved, Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Asenapine.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Asenapine.Approved
AvanafilAvanafil may increase the hypotensive activities of Asenapine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Asenapine is combined with Azaperone.Investigational, Vet Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Asenapine.Withdrawn
AzelastineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Asenapine is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Asenapine is combined with Azimilide.Investigational
AzithromycinAzithromycin may increase the QTc-prolonging activities of Asenapine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Asenapine is combined with Baclofen.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Asenapine.Investigational
BalsalazideBalsalazide may decrease the antihypertensive activities of Asenapine.Approved, Investigational
BambuterolAsenapine may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarbexacloneThe serum concentration of Asenapine can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Asenapine is combined with Barbital.Illicit
BarnidipineThe risk or severity of hypotension can be increased when Asenapine is combined with Barnidipine.Approved
BedaquilineBedaquiline may increase the QTc-prolonging activities of Asenapine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Asenapine.Experimental
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Asenapine.Investigational
BencyclaneThe risk or severity of hypotension can be increased when Asenapine is combined with Bencyclane.Experimental
BendazacBendazac may decrease the antihypertensive activities of Asenapine.Experimental
BenidipineThe risk or severity of hypotension can be increased when Asenapine is combined with Benidipine.Approved, Investigational
BenorilateBenorilate may decrease the antihypertensive activities of Asenapine.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Asenapine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Asenapine is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Asenapine is combined with Benzocaine.Approved, Investigational
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Asenapine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Asenapine is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineAsenapine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of hypotension can be increased when Asenapine is combined with Bepridil.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Asenapine.Approved, Investigational
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Asenapine.Approved, Investigational
BethanecholThe risk or severity of adverse effects can be increased when Asenapine is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved
BevantololAsenapine may increase the antihypertensive activities of Bevantolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Asenapine.Experimental
BioallethrinThe risk or severity of hypotension can be increased when Asenapine is combined with Bioallethrin.Approved, Experimental
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Asenapine.Approved
BitolterolAsenapine may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BL-1020BL-1020 may increase the hypotensive activities of Asenapine.Investigational
BoceprevirThe metabolism of Asenapine can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Asenapine.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
BosentanThe serum concentration of Asenapine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Asenapine.Approved
BrexpiprazoleAsenapine may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Asenapine.Approved, Illicit, Investigational
BromfenacBromfenac may decrease the antihypertensive activities of Asenapine.Approved
BromisovalThe risk or severity of adverse effects can be increased when Asenapine is combined with Bromisoval.Experimental
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Asenapine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Asenapine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Asenapine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Asenapine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucillamineBucillamine may decrease the antihypertensive activities of Asenapine.Investigational
BucindololBucindolol may increase the antihypertensive activities of Asenapine.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Asenapine.Approved, Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Asenapine.Investigational, Withdrawn
BufuralolBufuralol may increase the orthostatic hypotensive activities of Asenapine.Experimental, Investigational
BumadizoneBumadizone may decrease the antihypertensive activities of Asenapine.Experimental
BunazosinBunazosin may increase the antihypertensive activities of Asenapine.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Asenapine.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Asenapine.Approved
BuprenorphineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Asenapine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Asenapine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Asenapine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Asenapine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Asenapine is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Asenapine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Asenapine.Approved, Illicit, Vet Approved
CabergolineAsenapine may increase the vasoconstricting activities of Cabergoline.Approved
CaffeineThe metabolism of Asenapine can be decreased when combined with Caffeine.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Asenapine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Asenapine is combined with Canertinib.Investigational
CarbamazepineThe metabolism of Asenapine can be increased when combined with Carbamazepine.Approved, Investigational
CarbamoylcholineThe risk or severity of adverse effects can be increased when Asenapine is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Asenapine.Experimental, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Asenapine is combined with Carbinoxamine.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Asenapine is combined with Carboxyamidotriazole.Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Asenapine.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Asenapine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Asenapine is combined with Carisoprodol.Approved
CaroverineThe risk or severity of hypotension can be increased when Asenapine is combined with Caroverine.Experimental
CarprofenCarprofen may decrease the antihypertensive activities of Asenapine.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Asenapine.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Asenapine.Approved, Investigational
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Asenapine.Experimental
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Asenapine.Approved, Investigational
CefpodoximeAsenapine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CefuroximeAsenapine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CelecoxibCelecoxib may decrease the antihypertensive activities of Asenapine.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Asenapine.Approved, Investigational
CeritinibThe serum concentration of Asenapine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Asenapine is combined with Cetirizine.Approved
CevimelineThe risk or severity of adverse effects can be increased when Asenapine is combined with Cevimeline.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Asenapine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Asenapine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Asenapine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Asenapine is combined with Chloroprocaine.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Asenapine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Asenapine is combined with Chlorphenamine.Approved
ChlorphentermineAsenapine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the hypotensive activities of Asenapine.Experimental
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Asenapine.Approved, Investigational, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Asenapine.Approved, Investigational
ChlorprothixeneThe risk or severity of adverse effects can be increased when Asenapine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Asenapine is combined with Chlorzoxazone.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Asenapine.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Asenapine.Experimental
CilnidipineThe risk or severity of hypotension can be increased when Asenapine is combined with Cilnidipine.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Asenapine is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe risk or severity of hypotension can be increased when Asenapine is combined with Cinnarizine.Approved, Investigational
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
CirazolineAsenapine may decrease the vasoconstricting activities of Cirazoline.Experimental
CisaprideThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Asenapine.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Asenapine.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Asenapine.Approved
ClemastineThe metabolism of Asenapine can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolAsenapine may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Asenapine is combined with Clevidipine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Asenapine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Asenapine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Asenapine is combined with clomethiazole.Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Asenapine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Asenapine is combined with Clonazepam.Approved, Illicit
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved
ClonixinClonixin may decrease the antihypertensive activities of Asenapine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Asenapine is combined with Clopenthixol.Experimental
CloranololCloranolol may increase the orthostatic hypotensive activities of Asenapine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Asenapine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Asenapine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Asenapine.Approved
CobicistatThe metabolism of Asenapine can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Asenapine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Asenapine.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Asenapine.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Asenapine.Vet Approved
CrizotinibCrizotinib may increase the QTc-prolonging activities of Asenapine.Approved
CurcuminThe metabolism of Asenapine can be decreased when combined with Curcumin.Approved, Investigational
CyclandelateThe risk or severity of hypotension can be increased when Asenapine is combined with Cyclandelate.Approved
CyclizineThe risk or severity of adverse effects can be increased when Asenapine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Asenapine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Asenapine is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Asenapine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinAsenapine may increase the bradycardic activities of Cymarin.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Asenapine is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Asenapine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Asenapine.Approved, Investigational
DabrafenibThe serum concentration of Asenapine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Asenapine is combined with Dantrolene.Approved, Investigational
DapiprazoleDapiprazole may increase the antihypertensive activities of Asenapine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Asenapine.Investigational
DarodipineThe risk or severity of hypotension can be increased when Asenapine is combined with Darodipine.Experimental
DarunavirThe metabolism of Asenapine can be decreased when combined with Darunavir.Approved
DasatinibAsenapine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Asenapine.Approved
DeferasiroxThe serum concentration of Asenapine can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Asenapine.Approved
DelavirdineAsenapine can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DemecariumDemecarium may increase the bradycardic activities of Asenapine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Asenapine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Asenapine is combined with Deramciclane.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Asenapine.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
DeslanosideAsenapine may increase the bradycardic activities of Deslanoside.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Asenapine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Asenapine is combined with Desvenlafaxine.Approved, Investigational
DetomidineDetomidine may increase the atrioventricular blocking (AV block) activities of Asenapine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Asenapine is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Asenapine is combined with Dexbrompheniramine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved, Vet Approved
DexmethylphenidateAsenapine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
DextroamphetamineAsenapine may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Asenapine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Asenapine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Asenapine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Asenapine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Asenapine.Approved, Illicit, Investigational, Vet Approved
DichlorvosDichlorvos may increase the bradycardic activities of Asenapine.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Asenapine.Approved, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Asenapine is combined with Diethyl ether.Experimental
DiethylpropionAsenapine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Asenapine is combined with Difenoxin.Approved, Illicit
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Asenapine.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Asenapine.Approved, Investigational
DigitoxinAsenapine may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinAsenapine may increase the bradycardic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Asenapine may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Asenapine.Approved, Illicit
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Asenapine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Asenapine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Asenapine can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Asenapine is combined with Dimenhydrinate.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Asenapine.Approved, Illicit
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Asenapine.Approved
DistigmineDistigmine may increase the bradycardic activities of Asenapine.Experimental
DixyrazineThe risk or severity of adverse effects can be increased when Asenapine is combined with Dixyrazine.Experimental
DL-MethylephedrineDL-Methylephedrine may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved
DobutamineAsenapine may decrease the vasoconstricting activities of Dobutamine.Approved
DofetilideThe risk or severity of QTc prolongation can be increased when Dofetilide is combined with Asenapine.Approved, Investigational
DolasetronDolasetron may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
DomperidoneThe risk or severity of QTc prolongation can be increased when Domperidone is combined with Asenapine.Approved, Investigational, Vet Approved
DonepezilDonepezil may increase the bradycardic activities of Asenapine.Approved
DopexamineAsenapine may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Asenapine is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Asenapine can be decreased when combined with Dosulepin.Approved
DotarizineThe risk or severity of hypotension can be increased when Asenapine is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Asenapine.Approved
DoxepinAsenapine may increase the antihypertensive activities of Doxepin.Approved, Investigational
DoxofyllineAsenapine may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DoxycyclineThe metabolism of Asenapine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Asenapine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved, Illicit
DronedaroneDronedarone may increase the bradycardic activities of Asenapine.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Asenapine is combined with Drotebanol.Experimental, Illicit
DroxicamDroxicam may decrease the antihypertensive activities of Asenapine.Withdrawn
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Asenapine.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Asenapine is combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Asenapine.Investigational
DyclonineThe risk or severity of adverse effects can be increased when Asenapine is combined with Dyclonine.Approved
E-6201E-6201 may decrease the antihypertensive activities of Asenapine.Investigational
EcgonineThe risk or severity of adverse effects can be increased when Asenapine is combined with Ecgonine.Experimental, Illicit
EchothiophateEchothiophate may increase the bradycardic activities of Asenapine.Approved
EcopipamThe risk or severity of adverse effects can be increased when Asenapine is combined with Ecopipam.Investigational
EdrophoniumEdrophonium may increase the bradycardic activities of Asenapine.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Asenapine is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of hypotension can be increased when Asenapine is combined with Efonidipine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Asenapine.Approved, Investigational
EliglustatThe risk or severity of QTc prolongation can be increased when Asenapine is combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Asenapine is combined with Eltanolone.Investigational
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Asenapine.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Asenapine is combined with Enflurane.Approved, Investigational, Vet Approved
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Asenapine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Asenapine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Asenapine can be decreased when it is combined with Enzalutamide.Approved
EpanololEpanolol may increase the orthostatic hypotensive activities of Asenapine.Experimental
EperisoneThe risk or severity of hypotension can be increased when Asenapine is combined with Eperisone.Approved, Investigational
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved, Nutraceutical, Withdrawn
EphedrineAsenapine may decrease the vasoconstricting activities of Ephedrine.Approved
EpibatidineThe risk or severity of adverse effects can be increased when Asenapine is combined with Epibatidine.Experimental
EpinastineAsenapine may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineAsenapine may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Asenapine.Approved
Ergoloid mesylateAsenapine may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineAsenapine may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Asenapine.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Asenapine.Approved, Investigational, Vet Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Asenapine.Experimental
EscitalopramThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Asenapine.Approved, Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Asenapine.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Asenapine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Asenapine.Approved, Investigational
EtafedrineAsenapine may decrease the vasoconstricting activities of Etafedrine.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Asenapine.Approved, Investigational
EthanolAsenapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Asenapine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthenzamideEthenzamide may decrease the antihypertensive activities of Asenapine.Experimental
EthosuximideThe risk or severity of adverse effects can be increased when Asenapine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Asenapine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Asenapine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Asenapine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Asenapine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Asenapine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Asenapine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Asenapine is combined with Etifoxine.Investigational, Withdrawn
EtilefrineAsenapine may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Asenapine is combined with Etizolam.Approved
EtodolacEtodolac may decrease the antihypertensive activities of Asenapine.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Asenapine.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Asenapine is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Asenapine.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Asenapine is combined with Etorphine.Illicit, Vet Approved
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Asenapine.Investigational, Nutraceutical
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Asenapine.Approved, Investigational
ExisulindExisulind may decrease the antihypertensive activities of Asenapine.Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
FamotidineFamotidine may increase the QTc-prolonging activities of Asenapine.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Asenapine.Approved
FelbinacFelbinac may decrease the antihypertensive activities of Asenapine.Experimental
FelodipineThe risk or severity of hypotension can be increased when Asenapine is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Asenapine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Asenapine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe risk or severity of hypotension can be increased when Asenapine is combined with Fendiline.Withdrawn
FenoprofenFenoprofen may decrease the antihypertensive activities of Asenapine.Approved
FenoterolAsenapine may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Asenapine.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Asenapine.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Asenapine.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Asenapine.Experimental
Ferric CarboxymaltoseAsenapine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateAsenapine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferulic acidFerulic acid may decrease the antihypertensive activities of Asenapine.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Asenapine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Asenapine is combined with Fexofenadine.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Asenapine is combined with Fish oil.Approved, Nutraceutical
FlecainideFlecainide may increase the QTc-prolonging activities of Asenapine.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Asenapine is combined with Flibanserin.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Asenapine is combined with Floctafenine.Approved, Withdrawn
FluanisoneThe risk or severity of adverse effects can be increased when Asenapine is combined with Fluanisone.Experimental
FluconazoleFluconazole may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Asenapine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Asenapine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Asenapine is combined with Flunitrazepam.Approved, Illicit
FlunixinFlunixin may decrease the antihypertensive activities of Asenapine.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Asenapine.Experimental
FluoxetineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Asenapine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Asenapine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Asenapine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Asenapine.Approved, Illicit, Investigational
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Asenapine.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Asenapine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Asenapine is combined with Fluticasone propionate.Approved
FluvoxamineThe serum concentration of Asenapine can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Asenapine.Approved
FosaprepitantThe serum concentration of Asenapine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Asenapine.Approved
FosphenytoinThe metabolism of Asenapine can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Asenapine is combined with Fospropofol.Approved, Illicit, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Asenapine.Approved, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Asenapine.Approved, Investigational
Fusidic AcidThe serum concentration of Asenapine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Asenapine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Asenapine is combined with Gabapentin Enacarbil.Approved, Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
GalantamineGalantamine may increase the QTc-prolonging activities of Asenapine.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Asenapine.Approved
GallopamilThe risk or severity of hypotension can be increased when Asenapine is combined with Gallopamil.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Asenapine.Approved, Illicit, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Asenapine.Approved, Investigational
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
GepefrineAsenapine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Asenapine is combined with Gepirone.Investigational
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Asenapine.Approved, Investigational, Nutraceutical
GitoformateAsenapine may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Asenapine.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Asenapine.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Asenapine.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Asenapine.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Asenapine.Approved, Investigational
GlisoxepideAsenapine may increase the hypoglycemic activities of Glisoxepide.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Asenapine is combined with Glutethimide.Approved, Illicit
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Asenapine.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Asenapine.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
GTS-21The risk or severity of adverse effects can be increased when Asenapine is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Asenapine.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved, Investigational
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Asenapine.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Asenapine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the QTc-prolonging activities of Asenapine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Asenapine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Asenapine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Asenapine is combined with Hexobarbital.Approved
HexoprenalineAsenapine may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineAsenapine may decrease the vasoconstricting activities of Higenamine.Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Asenapine.Approved
Huperzine AHuperzine A may increase the bradycardic activities of Asenapine.Approved, Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Asenapine.Approved, Investigational
HydrocodoneAsenapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Asenapine.Approved, Illicit
HydroxyamphetamineAsenapine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxychloroquineThe metabolism of Asenapine can be decreased when combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
IbuprofenIbuprofen may decrease the antihypertensive activities of Asenapine.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Asenapine.Withdrawn
IbutilideThe risk or severity of QTc prolongation can be increased when Ibutilide is combined with Asenapine.Approved
IcatibantIcatibant may decrease the antihypertensive activities of Asenapine.Approved, Investigational
IdelalisibThe metabolism of Asenapine can be decreased when combined with Idelalisib.Approved
IloperidoneThe risk or severity of QTc prolongation can be increased when Iloperidone is combined with Asenapine.Approved
ImatinibThe metabolism of Asenapine can be decreased when combined with Imatinib.Approved
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Asenapine.Experimental
ImipramineAsenapine may increase the antihypertensive activities of Imipramine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Asenapine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Asenapine is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Asenapine.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Asenapine.Withdrawn
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Asenapine.Approved
IndiplonThe risk or severity of adverse effects can be increased when Asenapine is combined with Indiplon.Investigational
IndobufenIndobufen may decrease the antihypertensive activities of Asenapine.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Asenapine.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Asenapine.Withdrawn
IndoraminIndoramin may increase the antihypertensive activities of Asenapine.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Asenapine.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Asenapine.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Asenapine.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Asenapine.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Asenapine.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Asenapine.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Asenapine.Approved
Iofetamine I-123Asenapine may decrease the stimulatory activities of Iofetamine I-123.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Asenapine.Experimental
IronAsenapine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranAsenapine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateAsenapine can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsavuconazoleThe serum concentration of Asenapine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Asenapine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe therapeutic efficacy of Asenapine can be increased when used in combination with Isocarboxazid.Approved
IsoetarineAsenapine may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Asenapine.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Asenapine.Approved, Investigational, Withdrawn
IsomethepteneAsenapine may decrease the vasoconstricting activities of Isometheptene.Approved
IsoprenalineAsenapine may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
IsoxicamIsoxicam may decrease the antihypertensive activities of Asenapine.Withdrawn
IsoxsuprineAsenapine may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Asenapine.Approved, Investigational
IvabradineAsenapine may increase the QTc-prolonging activities of Ivabradine.Approved
IvacaftorThe serum concentration of Asenapine can be increased when it is combined with Ivacaftor.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Asenapine.Experimental
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Asenapine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Asenapine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Asenapine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Asenapine.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Asenapine.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Asenapine.Approved
LabetalolLabetalol may increase the antihypertensive activities of Asenapine.Approved
LacidipineThe risk or severity of hypotension can be increased when Asenapine is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Asenapine is combined with Lamotrigine.Approved, Investigational
Lanatoside CAsenapine may increase the bradycardic activities of Lanatoside C.Experimental
LandiololLandiolol may increase the orthostatic hypotensive activities of Asenapine.Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Asenapine.Approved
LeflunomideLeflunomide may decrease the antihypertensive activities of Asenapine.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
LercanidipineThe risk or severity of hypotension can be increased when Asenapine is combined with Lercanidipine.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Asenapine is combined with Levetiracetam.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Asenapine.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Asenapine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Asenapine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Asenapine is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Levodopa can be decreased when used in combination with Asenapine.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Asenapine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Asenapine is combined with Levomilnacipran.Approved, Investigational
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Asenapine.Approved
LevosalbutamolAsenapine may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Asenapine.Approved, Vet Approved
LidoflazineThe risk or severity of hypotension can be increased when Asenapine is combined with Lidoflazine.Experimental
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Asenapine.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Asenapine.Approved, Investigational
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Asenapine.Approved
LisdexamfetamineAsenapine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Asenapine.Investigational
Lithium cationLithium may increase the neurotoxic activities of Asenapine.Experimental
LobeglitazoneThe metabolism of Asenapine can be decreased when combined with Lobeglitazone.Approved, Investigational
LobelineThe risk or severity of adverse effects can be increased when Asenapine is combined with Lobeline.Investigational
LofentanilThe risk or severity of adverse effects can be increased when Asenapine is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Asenapine can be increased when used in combination with Lofexidine.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Asenapine.Experimental
LoperamideThe risk or severity of hypotension can be increased when Asenapine is combined with Loperamide.Approved
LopinavirThe risk or severity of QTc prolongation can be increased when Lopinavir is combined with Asenapine.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Asenapine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Asenapine is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Asenapine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Asenapine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Asenapine is combined with Lormetazepam.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Asenapine.Approved, Investigational
LorpiprazoleThe serum concentration of Asenapine can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Asenapine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Asenapine.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Asenapine.Approved, Investigational
LuliconazoleThe serum concentration of Asenapine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Asenapine can be increased when combined with Lumacaftor.Approved
LumefantrineThe risk or severity of QTc prolongation can be increased when Asenapine is combined with Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Asenapine.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Asenapine is combined with Lurasidone.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Asenapine.Approved
Magnesium sulfateThe therapeutic efficacy of Asenapine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MalathionMalathion may increase the bradycardic activities of Asenapine.Approved, Investigational
ManidipineThe risk or severity of hypotension can be increased when Asenapine is combined with Manidipine.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Asenapine.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Asenapine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Asenapine is combined with Meclizine.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Asenapine.Approved, Vet Approved
MedazepamThe risk or severity of adverse effects can be increased when Asenapine is combined with Medazepam.Experimental
MedetomidineMedetomidine may increase the atrioventricular blocking (AV block) activities of Asenapine.Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Asenapine.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Asenapine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Asenapine.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Asenapine is combined with Melperone.Approved, Investigational
MemantineMemantine may increase the bradycardic activities of Asenapine.Approved, Investigational
MentholThe risk or severity of hypotension can be increased when Asenapine is combined with Menthol.Approved
MephedroneAsenapine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineAsenapine may decrease the stimulatory activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Asenapine.Experimental
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Asenapine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Asenapine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Asenapine is combined with Meptazinol.Experimental
MequitazineAsenapine may increase the arrhythmogenic activities of Mequitazine.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Asenapine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Asenapine is combined with Mesoridazine.Approved, Investigational
MetahexamideAsenapine may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Asenapine.Approved, Investigational, Withdrawn
MetaraminolAsenapine may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Asenapine is combined with Metaxalone.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Asenapine.Approved
MethacholineAsenapine may increase the bronchoconstrictory activities of Methacholine.Approved, Investigational
MethadoneMethadone may increase the QTc-prolonging activities of Asenapine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Asenapine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Asenapine.Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Asenapine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Asenapine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Asenapine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Asenapine.Approved
MethotrimeprazineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxamineAsenapine may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Asenapine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineAsenapine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Asenapine is combined with Methsuximide.Approved
MethyldopaMethyldopa may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Asenapine is combined with Methylecgonine.Experimental
Methylene blueMethylene blue may increase the hypotensive activities of Asenapine.Approved, Investigational
MethylergometrineAsenapine may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Asenapine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Asenapine is combined with Methylphenobarbital.Approved
MetildigoxinAsenapine may increase the bradycardic activities of Metildigoxin.Experimental
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Asenapine.Approved, Investigational
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Asenapine.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Asenapine.Approved
MetyrosineAsenapine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Asenapine can be decreased when combined with Mexiletine.Approved, Investigational
MibefradilThe risk or severity of hypotension can be increased when Asenapine is combined with Mibefradil.Investigational, Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Asenapine.Approved, Illicit
MidodrineAsenapine may increase the bradycardic activities of Midodrine.Approved
MidomafetamineAsenapine may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Asenapine can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneAsenapine may increase the QTc-prolonging activities of Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Asenapine.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Asenapine.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Asenapine is combined with Milnacipran.Approved, Investigational
MinaprineMinaprine may increase the bradycardic activities of Asenapine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Asenapine.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Asenapine.Investigational
MirtazapineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Asenapine.Approved, Investigational
MitotaneThe serum concentration of Asenapine can be decreased when it is combined with Mitotane.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Asenapine.Investigational
MMDAAsenapine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Asenapine.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Asenapine.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Asenapine.Experimental
MolindoneThe risk or severity of adverse effects can be increased when Asenapine is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Asenapine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Asenapine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Asenapine.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Asenapine.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Asenapine.Approved
NadololNadolol may increase the orthostatic hypotensive activities of Asenapine.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Asenapine.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Asenapine.Approved
NaftopidilThe risk or severity of hypotension can be increased when Asenapine is combined with Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Asenapine.Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Asenapine.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Asenapine.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Asenapine.Approved, Investigational
NebivololNebivolol may increase the orthostatic hypotensive activities of Asenapine.Approved, Investigational
NefazodoneNefazodone may increase the antihypertensive activities of Asenapine.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Asenapine.Approved
NeostigmineNeostigmine may increase the bradycardic activities of Asenapine.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Asenapine.Approved, Investigational
NetupitantThe serum concentration of Asenapine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Asenapine can be increased when combined with Nevirapine.Approved
NicardipineAsenapine may increase the antihypertensive activities of Nicardipine.Approved, Investigational
NicergolineNicergoline may increase the antihypertensive activities of Asenapine.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Asenapine is combined with Nicotine.Approved
NifedipineThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Asenapine.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Asenapine.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Asenapine.Approved
NiguldipineAsenapine may increase the antihypertensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Asenapine.Approved, Investigational
NiludipineThe risk or severity of hypotension can be increased when Asenapine is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Asenapine is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Asenapine is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Asenapine is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Asenapine is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Asenapine.Approved
NitrendipineThe risk or severity of hypotension can be increased when Asenapine is combined with Nitrendipine.Approved, Investigational
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Asenapine.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Asenapine is combined with Nitrous oxide.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Asenapine is combined with Nordazepam.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved
NorfenefrineAsenapine may decrease the vasoconstricting activities of Norfenefrine.Experimental
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Asenapine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Asenapine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Asenapine is combined with Normethadone.Approved, Illicit
NortriptylineAsenapine may increase the antihypertensive activities of Nortriptyline.Approved
NylidrinAsenapine may decrease the vasoconstricting activities of Nylidrin.Approved
OctopamineAsenapine may decrease the vasoconstricting activities of Octopamine.Experimental
OctreotideOctreotide may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Asenapine.Approved
OlanzapineAsenapine may increase the antihypertensive activities of Olanzapine.Approved, Investigational
OlaparibThe metabolism of Asenapine can be decreased when combined with Olaparib.Approved
OleandrinAsenapine may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Asenapine.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Asenapine is combined with Olopatadine.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Asenapine.Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Asenapine.Approved
OpiumThe risk or severity of adverse effects can be increased when Asenapine is combined with Opium.Approved, Illicit
OrciprenalineAsenapine may decrease the vasoconstricting activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Asenapine.Vet Approved
OrphenadrineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Asenapine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Asenapine can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of hypotension can be increased when Asenapine is combined with Otilonium.Experimental, Investigational
OuabainAsenapine may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Asenapine.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Asenapine.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Asenapine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Asenapine is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Asenapine.Approved, Illicit, Investigational
OxyfedrineAsenapine may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Asenapine.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Asenapine.Approved, Withdrawn
OxytocinOxytocin may increase the QTc-prolonging activities of Asenapine.Approved, Vet Approved
PalbociclibThe serum concentration of Asenapine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of QTc prolongation can be increased when Paliperidone is combined with Asenapine.Approved
PalmidrolPalmidrol may decrease the antihypertensive activities of Asenapine.Experimental, Nutraceutical
PanobinostatPanobinostat may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
ParaldehydeAsenapine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParaoxonParaoxon may increase the bradycardic activities of Asenapine.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Asenapine.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Asenapine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Asenapine.Approved
PazopanibAsenapine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Peginterferon alfa-2bThe serum concentration of Asenapine can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Asenapine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Asenapine is combined with Penfluridol.Experimental
PentamidinePentamidine may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Asenapine.Approved, Vet Approved
PentobarbitalThe metabolism of Asenapine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Asenapine.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved
PerazineThe risk or severity of adverse effects can be increased when Asenapine is combined with Perazine.Approved, Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Asenapine.Approved
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Asenapine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Asenapine.Approved
PeruvosideAsenapine may increase the bradycardic activities of Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Asenapine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Asenapine is combined with Phenazocine.Experimental
PhendimetrazineAsenapine may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Asenapine.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Asenapine.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Asenapine is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Asenapine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Asenapine is combined with Phenoperidine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Asenapine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Asenapine is combined with Phenoxyethanol.Approved
PhentermineAsenapine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineAsenapine may increase the antihypertensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Asenapine.Approved, Vet Approved
PhenylephrineAsenapine may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineAsenapine may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Asenapine can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Asenapine.Approved, Investigational
PilocarpineThe risk or severity of adverse effects can be increased when Asenapine is combined with Pilocarpine.Approved, Investigational
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Asenapine.Approved, Investigational
PimozideThe risk or severity of QTc prolongation can be increased when Pimozide is combined with Asenapine.Approved
PinaveriumThe risk or severity of hypotension can be increased when Asenapine is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Asenapine.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Asenapine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Asenapine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Asenapine is combined with Pipotiazine.Approved, Investigational
PirbuterolAsenapine may decrease the vasoconstricting activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Asenapine.Approved, Investigational
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Asenapine.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Asenapine is combined with Piritramide.Approved, Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Asenapine.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Asenapine.Experimental
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Asenapine.Approved, Investigational
PizotifenAsenapine may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Asenapine.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Asenapine is combined with Pomalidomide.Approved
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Asenapine.Approved, Investigational, Vet Approved
PractololPractolol may increase the orthostatic hypotensive activities of Asenapine.Approved
PramipexoleAsenapine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Asenapine.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Asenapine is combined with Pramocaine.Approved
PranoprofenPranoprofen may decrease the antihypertensive activities of Asenapine.Experimental, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Asenapine is combined with Prazepam.Approved, Illicit
PrazosinPrazosin may increase the antihypertensive activities of Asenapine.Approved
PregabalinThe therapeutic efficacy of Asenapine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenalterolAsenapine may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Asenapine is combined with Prenylamine.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Asenapine is combined with Prilocaine.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Asenapine.Approved
PrimidoneThe metabolism of Asenapine can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of QTc prolongation can be increased when Procainamide is combined with Asenapine.Approved
ProcaineThe risk or severity of adverse effects can be increased when Asenapine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Asenapine.Approved, Investigational
ProcaterolAsenapine may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Asenapine.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Asenapine.Experimental
PromazinePromazine may increase the QTc-prolonging activities of Asenapine.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
PropacetamolPropacetamol may decrease the antihypertensive activities of Asenapine.Approved, Investigational
PropafenoneThe serum concentration of Asenapine can be increased when it is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Asenapine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Asenapine is combined with Proparacaine.Approved, Vet Approved
PropericiazineAsenapine may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazinePropiomazine may increase the antihypertensive activities of Asenapine.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Asenapine.Vet Approved
PropiverineAsenapine may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropofolPropofol may increase the QTc-prolonging activities of Asenapine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Asenapine is combined with Propoxycaine.Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Asenapine.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Asenapine.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Asenapine.Experimental
ProscillaridinAsenapine may increase the bradycardic activities of Proscillaridin.Experimental
ProtokylolAsenapine may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Asenapine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Asenapine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Asenapine is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved
PTC299PTC299 may decrease the antihypertensive activities of Asenapine.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Asenapine.Approved, Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Asenapine.Approved, Illicit
QuetiapineThe risk or severity of QTc prolongation can be increased when Quetiapine is combined with Asenapine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Asenapine.Approved, Investigational
QuinidineThe risk or severity of QTc prolongation can be increased when Quinidine is combined with Asenapine.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Quinine is combined with Asenapine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Asenapine is combined with Quinisocaine.Experimental
RacepinephrineAsenapine may increase the antihypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Asenapine is combined with Raclopride.Investigational
RactopamineAsenapine may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamelteonThe risk or severity of adverse effects can be increased when Asenapine is combined with Ramelteon.Approved, Investigational
RanolazineRanolazine may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Asenapine.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Asenapine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Asenapine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Asenapine is combined with Remoxipride.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Asenapine.Approved, Investigational
ReproterolAsenapine may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineReserpine may increase the hypotensive activities of Asenapine.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Asenapine.Approved, Experimental, Investigational
RifabutinThe metabolism of Asenapine can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Asenapine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Asenapine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Asenapine can be decreased when it is combined with Rifaximin.Approved, Investigational
RilmenidineAsenapine may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Asenapine.Approved
RimiterolAsenapine may decrease the vasoconstricting activities of Rimiterol.Experimental
RisedronateAsenapine can cause an increase in the absorption of Risedronate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
RisperidoneRisperidone may increase the antihypertensive activities of Asenapine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Asenapine is combined with Ritanserin.Investigational
RitobegronAsenapine may decrease the stimulatory activities of Ritobegron.Investigational
RitodrineAsenapine may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
RivastigmineAsenapine may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Asenapine.Approved
RofecoxibRofecoxib may decrease the antihypertensive activities of Asenapine.Approved, Investigational, Withdrawn
RomifidineRomifidine may increase the atrioventricular blocking (AV block) activities of Asenapine.Vet Approved
RopiniroleAsenapine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Asenapine is combined with Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Asenapine.Approved, Investigational
RotigotineAsenapine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Asenapine can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Asenapine.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Asenapine.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Asenapine.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Asenapine.Approved, Investigational, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Asenapine.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Asenapine.Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Asenapine.Approved, Investigational
SarilumabThe therapeutic efficacy of Asenapine can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Asenapine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Asenapine is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Asenapine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Asenapine.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Asenapine is combined with Seletracetam.Investigational
SemapimodSemapimod may decrease the antihypertensive activities of Asenapine.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Asenapine is combined with Sepranolone.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Asenapine.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Asenapine.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Asenapine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Asenapine.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Asenapine.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Asenapine.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Asenapine.Approved
SiltuximabThe serum concentration of Asenapine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Asenapine can be increased when it is combined with Simeprevir.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Asenapine.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved
SolabegronAsenapine may decrease the vasoconstricting activities of Solabegron.Investigational
SolifenacinSolifenacin may increase the QTc-prolonging activities of Asenapine.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Asenapine.Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Sotalol is combined with Asenapine.Approved
SRT501SRT501 may decrease the antihypertensive activities of Asenapine.Investigational
St. John's WortThe serum concentration of Asenapine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Asenapine can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Asenapine.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Asenapine.Approved
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Asenapine.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Asenapine.Approved, Vet Approved
SulindacSulindac may decrease the antihypertensive activities of Asenapine.Approved, Investigational
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Asenapine.Approved, Investigational
SulpirideAsenapine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Asenapine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Asenapine.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Asenapine.Approved, Withdrawn
SuvorexantAsenapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Asenapine.Experimental
SynephrineAsenapine may decrease the vasoconstricting activities of Synephrine.Experimental
TacrineTacrine may increase the bradycardic activities of Asenapine.Investigational, Withdrawn
TadalafilTadalafil may increase the hypotensive activities of Asenapine.Approved, Investigational
TafenoquineThe metabolism of Asenapine can be decreased when combined with Tafenoquine.Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Asenapine.Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Asenapine.Approved
TamsulosinTamsulosin may increase the antihypertensive activities of Asenapine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Asenapine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Asenapine.Investigational
TasimelteonThe risk or severity of adverse effects can be increased when Asenapine is combined with Tasimelteon.Approved, Investigational
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Asenapine.Approved
TelaprevirThe metabolism of Asenapine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Asenapine.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Asenapine.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Asenapine.Approved, Investigational
TenidapTenidap may decrease the antihypertensive activities of Asenapine.Experimental
Tenofovir disoproxilThe metabolism of Asenapine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Asenapine.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Asenapine.Vet Approved
TerazosinTerazosin may increase the antihypertensive activities of Asenapine.Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Asenapine.Approved
TeriflunomideThe serum concentration of Asenapine can be decreased when it is combined with Teriflunomide.Approved
TerodilineThe risk or severity of hypotension can be increased when Asenapine is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Asenapine.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Asenapine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Asenapine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Asenapine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Asenapine is combined with Tetrodotoxin.Investigational
TetryzolineAsenapine may decrease the vasoconstricting activities of Tetryzoline.Approved
ThalidomideAsenapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the hypotensive activities of Asenapine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Asenapine is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Asenapine.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Asenapine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Asenapine is combined with Thiopental.Approved, Vet Approved
ThioproperazineAsenapine may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Asenapine.Approved, Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Asenapine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Asenapine is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Asenapine is combined with Tiapride.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Asenapine.Approved
TiclopidineThe metabolism of Asenapine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Asenapine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Asenapine is combined with Tilidine.Experimental
TimololTimolol may increase the orthostatic hypotensive activities of Asenapine.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Asenapine.Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
TocilizumabThe serum concentration of Asenapine can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Asenapine.Approved, Investigational
TolazolineTolazoline may increase the antihypertensive activities of Asenapine.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Asenapine.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Asenapine is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of hypotension can be increased when Asenapine is combined with Tolfenamic Acid.Approved, Investigational
TolmetinTolmetin may decrease the antihypertensive activities of Asenapine.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Asenapine is combined with Topiramate.Approved
ToremifeneThe risk or severity of QTc prolongation can be increased when Toremifene is combined with Asenapine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Asenapine.Approved, Investigational
TranilastThe risk or severity of hypotension can be increased when Asenapine is combined with Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Asenapine is combined with Tranylcypromine.Approved, Investigational
TrazodoneTrazodone may increase the antihypertensive activities of Asenapine.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
TretoquinolAsenapine may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Asenapine.Approved, Investigational
TribenosideTribenoside may decrease the antihypertensive activities of Asenapine.Experimental
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Asenapine is combined with Tricaine methanesulfonate.Vet Approved
TrichlorfonTrichlorfon may increase the bradycardic activities of Asenapine.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Asenapine is combined with Trichloroethylene.Approved
TrifluoperazineTrifluoperazine may increase the antihypertensive activities of Asenapine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Asenapine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Asenapine is combined with Triflupromazine.Approved, Vet Approved
TrimazosinTrimazosin may increase the antihypertensive activities of Asenapine.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Asenapine is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Asenapine is combined with Trimethadione.Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Asenapine.Approved, Vet Approved
TrimipramineAsenapine may increase the antihypertensive activities of Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Asenapine is combined with Triprolidine.Approved
TriptolideTriptolide may decrease the antihypertensive activities of Asenapine.Investigational
TriptorelinTriptorelin may increase the QTc-prolonging activities of Asenapine.Approved, Vet Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Asenapine.Investigational, Withdrawn
TubocurarineTubocurarine may increase the bradycardic activities of Asenapine.Approved
TulobuterolAsenapine may decrease the vasoconstricting activities of Tulobuterol.Investigational
TyrothricinTyrothricin may increase the bradycardic activities of Asenapine.Approved
UdenafilUdenafil may increase the hypotensive activities of Asenapine.Approved, Investigational
UrapidilUrapidil may increase the antihypertensive activities of Asenapine.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Asenapine.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Asenapine is combined with Valproic Acid.Approved, Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Vandetanib is combined with Asenapine.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Asenapine.Approved
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Asenapine.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Asenapine.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Asenapine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Asenapine is combined with Veralipride.Experimental
VerapamilAsenapine may increase the antihypertensive activities of Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Asenapine is combined with Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Asenapine.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Asenapine.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Asenapine.Approved, Investigational
VinpocetineThe risk or severity of hypotension can be increased when Asenapine is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Asenapine is combined with Vinyl ether.Experimental
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Asenapine.Approved, Investigational
VoriconazoleThe metabolism of Asenapine can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Asenapine.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Asenapine is combined with Vortioxetine.Approved, Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Asenapine is combined with WIN 55212-2.Experimental
XamoterolAsenapine may decrease the vasoconstricting activities of Xamoterol.Experimental
XenonThe risk or severity of adverse effects can be increased when Asenapine is combined with Xenon.Experimental
XylazineXylazine may increase the atrioventricular blocking (AV block) activities of Asenapine.Vet Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Asenapine.Approved, Illicit, Investigational
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Asenapine.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Asenapine is combined with Ziconotide.Approved
ZileutonZileuton may decrease the antihypertensive activities of Asenapine.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of adverse effects can be increased when Asenapine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Asenapine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Asenapine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Asenapine.Approved, Investigational
ZolpidemAsenapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracZomepirac may decrease the antihypertensive activities of Asenapine.Withdrawn
ZonisamideThe risk or severity of adverse effects can be increased when Asenapine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Asenapine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Asenapine is combined with Zotepine.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Asenapine can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Asenapine.Approved, Investigational
Food Interactions
  • Avoid water and food for at least 10 minutes post administration of asenapine

References

Synthesis Reference
US4145434
General References
  1. Huang M, Li Z, Dai J, Shahid M, Wong EH, Meltzer HY: Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacology. 2008 Nov;33(12):2934-45. doi: 10.1038/npp.2008.20. Epub 2008 Apr 16. [PubMed:18418367]
  2. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
  3. Franberg O, Wiker C, Marcus MM, Konradsson A, Jardemark K, Schilstrom B, Shahid M, Wong EH, Svensson TH: Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl). 2008 Feb;196(3):417-29. Epub 2007 Oct 17. [PubMed:17940749]
  4. Fagiolini A, Forgione RN, Morana B, Maccari M, Goracci A, Bossini L, Pellegrini F, Cuomo A, Casamassima F: Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice. Expert Opin Pharmacother. 2013 Mar;14(4):489-504. doi: 10.1517/14656566.2013.765859. Epub 2013 Jan 29. [PubMed:23356509]
External Links
KEGG Drug
D02995
PubChem Compound
11954293
PubChem Substance
175427062
ChemSpider
10128588
ChEBI
71253
ChEMBL
CHEMBL3544974
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Asenapine
ATC Codes
N05AH05 — Asenapine
AHFS Codes
  • 28:16.08.04 — Atypical Antipsychotics
FDA label
Download (448 KB)
MSDS
Download (91.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableBipolar Disorder (BD) / Schizophrenic Disorders1
1CompletedTreatmentBipolar I Disorder / Schizophrenic Disorders1
2CompletedOtherPsychosis1
2RecruitingTreatmentDepression, Bipolar1
3CompletedTreatmentBipolar 1 Disorder2
3CompletedTreatmentBipolar Disorder (BD)7
3CompletedTreatmentBipolar Disorder, Pediatric1
3CompletedTreatmentBipolar I Disorder1
3CompletedTreatmentPsychosis1
3CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders2
3CompletedTreatmentSchizophrenia, Disorganized / Schizophrenia, paranoid type / Schizophrenia, Undifferentiated2
3CompletedTreatmentSchizophrenic Disorders15
3SuspendedTreatmentStuttering1
3Unknown StatusTreatmentPsychosis Nos/Other1
4CompletedTreatmentAcute Agitation1
4CompletedTreatmentBipolar Disorder (BD)1
4CompletedTreatmentMajor Depressive Disorder Without Psychotic Features1
4CompletedTreatmentPosttraumatic Stress Disorders1
4CompletedTreatmentPsychotic Disorder NOS1
4CompletedTreatmentSchizophrenic Disorders1
4Unknown StatusTreatmentDisorders / Schizophrenia and Disorders With Psychotic Features1
Not AvailableActive Not RecruitingNot AvailableSchizophrenic Disorders1
Not AvailableCompletedNot AvailableBipolar Disorder (BD)1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletSublingual10 mg/1
TabletSublingual10 mg
TabletSublingual2.5 mg/1
TabletSublingual5 mg
TabletSublingual5 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5763476Yes2000-12-092020-12-09Us
US7741358Yes2006-10-062026-10-06Us
US8022228Yes2006-10-062026-10-06Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP3.72ChemAxon
pKa (Strongest Basic)7.29ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity81.65 m3·mol-1ChemAxon
Polarizability30.9 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9849
Blood Brain Barrier+0.8842
Caco-2 permeable+0.5605
P-glycoprotein substrateSubstrate0.7617
P-glycoprotein inhibitor INon-inhibitor0.9375
P-glycoprotein inhibitor IINon-inhibitor0.8901
Renal organic cation transporterNon-inhibitor0.7054
CYP450 2C9 substrateNon-substrate0.7964
CYP450 2D6 substrateNon-substrate0.7864
CYP450 3A4 substrateSubstrate0.5065
CYP450 1A2 substrateNon-inhibitor0.5212
CYP450 2C9 inhibitorNon-inhibitor0.7185
CYP450 2D6 inhibitorNon-inhibitor0.6781
CYP450 2C19 inhibitorNon-inhibitor0.5762
CYP450 3A4 inhibitorNon-inhibitor0.8625
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6005
Ames testNon AMES toxic0.5417
CarcinogenicityNon-carcinogens0.8694
BiodegradationNot ready biodegradable0.9894
Rat acute toxicity2.7083 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8125
hERG inhibition (predictor II)Non-inhibitor0.6697
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzoxepines. These are compounds containing a dibenzoxepine moiety, which consists of two benzene connected by an oxazepine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzoxepines
Sub Class
Dibenzoxepines
Direct Parent
Dibenzoxepines
Alternative Parents
Diarylethers / Aralkylamines / Unsaturated fatty acids / Aryl chlorides / N-alkylpyrrolidines / Benzenoids / Dicarboxylic acids and derivatives / Trialkylamines / Oxacyclic compounds / Azacyclic compounds
show 6 more
Substituents
Dibenzoxepine / Diaryl ether / Aralkylamine / Aryl chloride / Aryl halide / Dicarboxylic acid or derivatives / Unsaturated fatty acid / N-alkylpyrrolidine / Benzenoid / Fatty acid
show 21 more
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Citrome L: Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:325-39. doi: 10.2147/NDT.S16077. Epub 2011 May 26. [PubMed:21655346]
  2. Tadori Y, Forbes RA, McQuade RD, Kikuchi T: Functional potencies of dopamine agonists and antagonists at human dopamine D(2) and D(3) receptors. Eur J Pharmacol. 2011 Sep;666(1-3):43-52. doi: 10.1016/j.ejphar.2011.05.050. Epub 2011 Jun 1. [PubMed:21658377]
  3. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
  2. Citrome L: Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:325-39. doi: 10.2147/NDT.S16077. Epub 2011 May 26. [PubMed:21655346]
  3. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
  2. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1B
Uniprot ID
P28222
Uniprot Name
5-hydroxytryptamine receptor 1B
Molecular Weight
43567.535 Da
References
  1. Citrome L: Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:325-39. doi: 10.2147/NDT.S16077. Epub 2011 May 26. [PubMed:21655346]
  2. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation...
Gene Name
HTR2B
Uniprot ID
P41595
Uniprot Name
5-hydroxytryptamine receptor 2B
Molecular Weight
54297.41 Da
References
  1. Citrome L: Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:325-39. doi: 10.2147/NDT.S16077. Epub 2011 May 26. [PubMed:21655346]
  2. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
  2. Citrome L: Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:325-39. doi: 10.2147/NDT.S16077. Epub 2011 May 26. [PubMed:21655346]
  3. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR5A
Uniprot ID
P47898
Uniprot Name
5-hydroxytryptamine receptor 5A
Molecular Weight
40254.69 Da
References
  1. Citrome L: Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:325-39. doi: 10.2147/NDT.S16077. Epub 2011 May 26. [PubMed:21655346]
  2. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR6
Uniprot ID
P50406
Uniprot Name
5-hydroxytryptamine receptor 6
Molecular Weight
46953.625 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
  2. Citrome L: Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:325-39. doi: 10.2147/NDT.S16077. Epub 2011 May 26. [PubMed:21655346]
  3. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR7
Uniprot ID
P34969
Uniprot Name
5-hydroxytryptamine receptor 7
Molecular Weight
53554.43 Da
References
  1. Citrome L: Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:325-39. doi: 10.2147/NDT.S16077. Epub 2011 May 26. [PubMed:21655346]
  2. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Citrome L: Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:325-39. doi: 10.2147/NDT.S16077. Epub 2011 May 26. [PubMed:21655346]
  2. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Citrome L: Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:325-39. doi: 10.2147/NDT.S16077. Epub 2011 May 26. [PubMed:21655346]
  2. Tadori Y, Forbes RA, McQuade RD, Kikuchi T: Functional potencies of dopamine agonists and antagonists at human dopamine D(2) and D(3) receptors. Eur J Pharmacol. 2011 Sep;666(1-3):43-52. doi: 10.1016/j.ejphar.2011.05.050. Epub 2011 Jun 1. [PubMed:21658377]
  3. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
  2. Citrome L: Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:325-39. doi: 10.2147/NDT.S16077. Epub 2011 May 26. [PubMed:21655346]
  3. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Citrome L: Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:325-39. doi: 10.2147/NDT.S16077. Epub 2011 May 26. [PubMed:21655346]
  2. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and diff...
Gene Name
HRH2
Uniprot ID
P25021
Uniprot Name
Histamine H2 receptor
Molecular Weight
40097.65 Da
References
  1. Citrome L: Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:325-39. doi: 10.2147/NDT.S16077. Epub 2011 May 26. [PubMed:21655346]
  2. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Fagiolini A, Forgione RN, Morana B, Maccari M, Goracci A, Bossini L, Pellegrini F, Cuomo A, Casamassima F: Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice. Expert Opin Pharmacother. 2013 Mar;14(4):489-504. doi: 10.1517/14656566.2013.765859. Epub 2013 Jan 29. [PubMed:23356509]
  2. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Fagiolini A, Forgione RN, Morana B, Maccari M, Goracci A, Bossini L, Pellegrini F, Cuomo A, Casamassima F: Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice. Expert Opin Pharmacother. 2013 Mar;14(4):489-504. doi: 10.1517/14656566.2013.765859. Epub 2013 Jan 29. [PubMed:23356509]
  2. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Citrome L: Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:325-39. doi: 10.2147/NDT.S16077. Epub 2011 May 26. [PubMed:21655346]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Citrome L: Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:325-39. doi: 10.2147/NDT.S16077. Epub 2011 May 26. [PubMed:21655346]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein homodimerization activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A4
Uniprot ID
P22310
Uniprot Name
UDP-glucuronosyltransferase 1-4
Molecular Weight
60024.535 Da
References
  1. Fagiolini A, Forgione RN, Morana B, Maccari M, Goracci A, Bossini L, Pellegrini F, Cuomo A, Casamassima F: Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice. Expert Opin Pharmacother. 2013 Mar;14(4):489-504. doi: 10.1517/14656566.2013.765859. Epub 2013 Jan 29. [PubMed:23356509]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Fagiolini A, Forgione RN, Morana B, Maccari M, Goracci A, Bossini L, Pellegrini F, Cuomo A, Casamassima F: Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice. Expert Opin Pharmacother. 2013 Mar;14(4):489-504. doi: 10.1517/14656566.2013.765859. Epub 2013 Jan 29. [PubMed:23356509]

Drug created on March 19, 2008 10:17 / Updated on July 13, 2018 01:09